1. Disease Information

1.1 What is the disease? (concise overview)

ACV/CSVV/LCV is a small-vessel vasculitis of the skin in which inflammation primarily targets superficial dermal post-capillary venules, producing palpable purpura and related purpuric/urticarial lesions, most often on dependent areas (lower legs). It is typically immune-complex–mediated with complement activation, and may be idiopathic or triggered by drugs/infections; it can also reflect systemic vasculitis or systemic disease and thus requires evaluation for extracutaneous involvement. (micheletti2023cutaneoussmallvessel pages 1-2, micheletti2023cutaneoussmallvessel pages 2-5)

1.2 Key identifiers (ontology / coding)

• MeSH: Vasculitis, Leukocytoclastic, Cutaneous — D018366 (NCT02550080 chunk 2)
• ICD-10(-CM) codes used in large EHR research for LCV/cutaneous LCV: D69.0 and L95.8 (takatu2017clinicopathologiccorrelationof pages 1-2)
• MONDO / Orphanet / OMIM: Not found in the retrieved sources; ACV/CSVV is generally treated as an acquired clinical-pathologic syndrome rather than a single-gene disorder in the dermatology/rheumatology literature summarized here. (micheletti2023cutaneoussmallvessel pages 1-2)

1.3 Common synonyms / alternative names

• Cutaneous small-vessel vasculitis (CSVV)
• Cutaneous leukocytoclastic vasculitis (LCV)
• Leukocytoclastic vasculitis
• Hypersensitivity vasculitis
• Cutaneous leukocytoclastic angiitis (micheletti2023cutaneoussmallvessel pages 1-2)

1.4 Evidence sources

The information summarized here is derived from aggregated disease-level resources (reviews/guides) plus clinical cohorts/case series, not from a single EHR system except where explicitly noted (e.g., DIF cohort; population estimates; EHR database cohort). (micheletti2023cutaneoussmallvessel pages 5-6, fraticelli2021diagnosisandmanagement pages 1-2, takatu2017clinicopathologiccorrelationof pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic)

The prevailing model is immune complex deposition in small cutaneous vessels with complement activation and neutrophil recruitment/activation, leading to vessel wall injury (fibrinoid necrosis), leukocytoclasia, and red blood cell extravasation (purpura). (micheletti2023cutaneoussmallvessel pages 1-2, fadel2025healthliteracyand pages 3-5)

2.2 Risk factors (clinical triggers and associated conditions)

Frequently reported triggers/associations include: - Medications (antibiotics, including beta-lactams, among common triggers) (micheletti2023cutaneoussmallvessel pages 2-5) - Infections (e.g., upper respiratory infections, Group A Streptococcus, hepatitis C) (micheletti2023cutaneoussmallvessel pages 2-5) - Systemic inflammatory/autoimmune disease (connective tissue diseases; ANCA-associated vasculitis; cryoglobulinemia; IgA vasculitis; urticarial vasculitis) (fraticelli2021diagnosisandmanagement pages 1-2) - Malignancy (less common): LCV may rarely be a paraneoplastic clue; reviews emphasize malignancy as a possible association that should be considered based on clinical context. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2)

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved sources.

2.4 Gene–environment interactions

Not well defined for ACV/CSVV specifically in the retrieved sources. Mechanistically, type III immune complex reactions are driven by antigen exposure (infection/drug antigen) leading to immune-complex formation and complement activation. (fadel2025healthliteracyand pages 3-5, sunderkotter2023pathophysiologyandclinical pages 2-3)

3. Phenotypes

3.1 Core cutaneous phenotypes (with HPO suggestions)

Common skin manifestations (adult and pediatric literature overlap, but this report emphasizes adult CSVV/LCV): - Palpable purpura (dependent distribution, often lower legs) — suggested HPO: Purpura (HP:0000979) (micheletti2023cutaneoussmallvessel pages 1-2) - Petechiae / non-blanching purpura — suggested HPO: Petechiae (HP:0000967) (micheletti2023cutaneoussmallvessel pages 2-5) - Urticarial papules / wheals (esp. in urticarial vasculitis overlap) — suggested HPO: Urticaria (HP:0001025) (rothermel2024managingurticarialvasculitis pages 1-2) - Hemorrhagic vesicles/pustules (subset) — suggested HPO: Vesicle (HP:0001598) / Pustule (HP:0000966) (micheletti2023cutaneoussmallvessel pages 1-2) - Ulceration/necrosis/retiform purpura may indicate more severe disease or larger-vessel involvement and triggers expanded systemic evaluation — suggested HPO: Skin ulcer (HP:0001059) / Skin necrosis (HP:0025478) (micheletti2023cutaneoussmallvessel pages 2-5)

Extracutaneous symptoms (when present): - Arthralgia is commonly reported among extracutaneous symptoms — suggested HPO: Arthralgia (HP:0002829) (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15)

3.2 Phenotype characteristics

• Onset pattern: commonly acute episodes; many are self-limited over weeks (micheletti2023cutaneoussmallvessel pages 2-5)
• Frequency/severity example (clinical cohort): in a 75-patient series, lesions affected only lower limbs in 80% and presented as palpable purpura in 64%. (micheletti2023cutaneoussmallvessel pages 2-5)

3.3 Quality of life impact

Recent guidance emphasizes that cutaneous vasculitis can significantly impact patients and that management can be challenging despite skin-limited disease. (micheletti2023cutaneoussmallvessel pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes / pathogenic variants

Not established for typical ACV/CSVV: the retrieved clinical guidance treats CSVV/LCV largely as an acquired immune-mediated syndrome rather than a monogenic disorder. (micheletti2023cutaneoussmallvessel pages 1-2, fraticelli2021diagnosisandmanagement pages 1-2)

4.2 Modifier genes / epigenetics / chromosomal abnormalities

Not identified in the retrieved sources for ACV/CSVV.

Important “genetic mimic” note (clinical differential): monogenic autoinflammatory diseases can present with cutaneous vasculitis phenotypes in other contexts, but specific gene-level evidence for ACV/CSVV was not extracted from the retrieved texts in this run. (fraticelli2021diagnosisandmanagement pages 1-2)

5. Environmental Information

5.1 Environmental and lifestyle factors

No specific pollutant/toxin/lifestyle risks were identified in the retrieved sources, beyond exposure to triggering antigens such as medications and infections. (micheletti2023cutaneoussmallvessel pages 2-5)

5.2 Infectious agents

Upper respiratory infections, Group A Streptococcus, and hepatitis C are highlighted as common or notable triggers/associations in CSVV/LCV reviews. (micheletti2023cutaneoussmallvessel pages 2-5)

6. Mechanism / Pathophysiology

6.1 Causal chain (trigger → lesion)

A widely used mechanistic chain for immune-complex (type III) cutaneous vasculitis is: 1) Antigen exposure → 2) IgG formation and immune complex formation → 3) Immune complex deposition → 4) Classical complement cascade activation (C3a/C5a generation) → 5) mast cell degranulation and histamine release → 6) neutrophil recruitment and degranulation → 7) fibrinoid necrosis of vessel walls and leukocytoclasia → 8) RBC extravasation causing non-blanching purpura. (fadel2025healthliteracyand pages 3-5)

6.2 Immune-complex vasculitis and NETosis (recent developments)

A 2023 synthesis of immune-complex vasculitides highlights polymorphonuclear neutrophil activation via Fc receptors and notes that in IgA vasculitis, intravascular priming of neutrophils can lead to vessel-destructive NETosis upon encountering deposited IgA at vessel walls, linking Fcα receptor biology to NET formation and vascular injury. (sunderkotter2023pathophysiologyandclinical pages 1-2)

A 2024 pathology-focused review emphasizes that newer insights (including NETosis) are increasingly integrated into understanding of vasculitis initiation and progression. (cassisa2024cutaneousvasculitisinsights pages 1-2)

6.3 Key cellular players (CL term suggestions)

• Neutrophil — suggested CL: neutrophil (CL:0000775) (sunderkotter2023pathophysiologyandclinical pages 1-2)
• Endothelial cell — suggested CL: endothelial cell (CL:0000115) (cassisa2024cutaneousvasculitisinsights pages 1-2)
• Mast cell — suggested CL: mast cell (CL:0000097) (fadel2025healthliteracyand pages 3-5)

6.4 Key pathways and processes (GO term suggestions)

• Immune complex clearance / immune complex deposition — suggested GO: immune complex clearance (GO:0006956) (sunderkotter2023pathophysiologyandclinical pages 2-3)
• Complement activation (classical pathway) — suggested GO: classical complement activation (GO:0006958) (fadel2025healthliteracyand pages 3-5)
• Neutrophil chemotaxis and activation — suggested GO: neutrophil chemotaxis (GO:0030593) (fadel2025healthliteracyand pages 3-5)
• NET formation — suggested GO: neutrophil extracellular trap formation (GO:0036416) (sunderkotter2023pathophysiologyandclinical pages 1-2)

6.5 Tissue damage mechanism

Histopathologic injury includes fibrinoid necrosis of small vessels with neutrophilic infiltration and nuclear debris (leukocytoclasia), which can be visualized on H&E sections. (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15, cassisa2024cutaneousvasculitisinsights media af7d9316)

7. Anatomical Structures Affected

7.1 Organ/tissue level

• Primary: skin (dermis), especially post-capillary venules in superficial dermis (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15, sunderkotter2023pathophysiologyandclinical pages 2-3)
• Secondary involvement to screen for: kidney (occult glomerulonephritis), joints, peripheral nerves depending on systemic features and subtype (fraticelli2021diagnosisandmanagement pages 1-2, micheletti2023cutaneoussmallvessel pages 2-5)

UBERON suggestions: - Skin — UBERON:0002097 - Dermis — UBERON:0002067

8. Temporal Development

8.1 Onset and course

• Often acute with episodes that may be self-limited. Many cases resolve within ~3–4 weeks. (micheletti2023cutaneoussmallvessel pages 2-5)
• Chronicity: a subset becomes chronic or recurrent; one guide cites ~10% chronic/relapsing disease. (micheletti2023cutaneoussmallvessel pages 6-7)

9. Inheritance and Population

9.1 Epidemiology (recently summarized statistics)

A highly cited clinical review reports wide variability in reported epidemiology for biopsy-proven cutaneous LCV: - Incidence: 15–38 per million/year - Prevalence: 2.7–29.7 per million - A U.S. population study estimate for biopsy-proven LCV: 4.5 per 100,000 person-years (95% CI 3.5–5.4) (fraticelli2021diagnosisandmanagement pages 1-2)

9.2 Demographics

Cutaneous LCV affects both sexes and all ages; some studies report a slight male/older-age predilection. (fraticelli2021diagnosisandmanagement pages 2-3)

9.3 Inheritance

No Mendelian inheritance pattern is established for typical ACV/CSVV in the retrieved sources (acquired immune-mediated condition). (micheletti2023cutaneoussmallvessel pages 1-2)

10. Diagnostics

10.1 Clinical approach (real-world implementation)

A recent practical guide emphasizes history, exam, and review of systems to identify triggers and to distinguish skin-limited disease from systemic vasculitis. A targeted stepwise workup is favored, with broad testing reserved for systemic features. (micheletti2023cutaneoussmallvessel pages 2-5, micheletti2023cutaneoussmallvessel pages 5-6)

10.2 Laboratory tests (core and extended)

Minimal baseline tests for straightforward, skin-limited presentations (per dermatology guidance): - CBC - Basic metabolic panel / renal function - Urinalysis with microscopic review (screen for occult glomerulonephritis) (micheletti2023cutaneoussmallvessel pages 2-5)

Commonly used broader evaluation (particularly if systemic involvement is suspected): - Platelet count - Hepatitis B and C serologies - ANA and ANCA - Complement fractions - IgA staining in biopsy specimens (fraticelli2021diagnosisandmanagement pages 1-2)

10.3 Biopsy and immunopathology

• Timing: biopsy ideally from a lesion ~24–48 hours old / 1–2 days old to optimize diagnostic yield (micheletti2023cutaneoussmallvessel pages 1-2)
• Histology: neutrophilic inflammation, leukocytoclasia, fibrinoid necrosis, and RBC extravasation (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15, fraticelli2021diagnosisandmanagement pages 1-2)
• Direct immunofluorescence (DIF): recommended; in a large cohort, DIF was positive in 70.21% and systemic involvement occurred in 12.5% (takatu2017clinicopathologiccorrelationof pages 1-2). DIF is reported to be ~80% sensitive/specific for IgA vasculitis in a dermatology guide. (micheletti2023cutaneoussmallvessel pages 1-2)

10.4 Differential diagnosis

Key systemic associations to consider include ANCA-associated vasculitis, connective tissue diseases (e.g., SLE), cryoglobulinemic vasculitis, IgA vasculitis, and hypocomplementemic urticarial vasculitis. (fraticelli2021diagnosisandmanagement pages 1-2)

11. Outcome / Prognosis

11.1 Overall prognosis

A practical dermatology guide reports a generally favorable course: - ~90% resolve spontaneously within weeks to months - ~10% develop a chronic/relapsing course that may last months to years (micheletti2023cutaneoussmallvessel pages 6-7)

11.2 Prognostic factors (clinical)

Prognosis depends strongly on whether disease is skin-limited versus reflecting a systemic vasculitis/systemic disease, emphasizing the importance of accurate classification and systemic screening. (micheletti2023cutaneoussmallvessel pages 6-7)

12. Treatment

12.1 Treatment principles (current practice)

• First-line for most acute skin-limited episodes: supportive measures (rest, elevation, compression), topical steroids/NSAIDs if appropriate, plus removal of the trigger (stop offending drug; treat infection). (micheletti2023cutaneoussmallvessel pages 2-5, escamilla2024vasculitisleucocitoclásticaasociada pages 10-15)
• Avoid aggressive long-term immunosuppression for purely skin-limited disease; reserve systemic therapy for severe, intractable, or recurrent cases. (micheletti2023cutaneoussmallvessel pages 2-5, micheletti2023cutaneoussmallvessel pages 5-6)

12.2 Common systemic therapies and dosing (real-world implementation)

From a 2023 practical guide: - Colchicine: 0.6 mg twice daily - Dapsone: 100–150 mg/day (screen for G6PD deficiency) - Azathioprine: target 2 mg/kg/day (screen TPMT) (micheletti2023cutaneoussmallvessel pages 5-6)

Oral glucocorticoids may be used for severe symptomatic disease (example regimens): - Prednisone ~0.5–1 mg/kg/day or 40–60 mg/day, tapered over 3–4 weeks; not appropriate as a long-term plan due to toxicity. (micheletti2023cutaneoussmallvessel pages 5-6, micheletti2023cutaneoussmallvessel pages 6-7)

Escalation options for refractory disease include mycophenolate mofetil, methotrexate, hydroxychloroquine, pentoxifylline, and (for severe refractory cases) rituximab, infliximab, IVIG, cyclosporine, cyclophosphamide. (micheletti2023cutaneoussmallvessel pages 5-6, micheletti2023cutaneoussmallvessel pages 6-7)

12.3 Trials / experimental evidence

• ARAMIS trial (ongoing at the time of the guide): international randomized trial for colchicine in CSVV/LCV (ClinicalTrials.gov identifier NCT02939573) was cited as ongoing in the 2023 guide. (micheletti2023cutaneoussmallvessel pages 5-6)
• Additional vasculitis-related observational/interventional trials relevant to immune-complex vasculitis phenotyping and relapse prevention include studies comparing IgA-positive vs IgA-negative immune complex vasculitis (NCT01815190) and adult IgA vasculitis relapse prevention with colchicine (NCT04008316). (NCT01815190 chunk 1, NCT04008316 chunk 2)

MAXO suggestions (treatment actions): - Systemic glucocorticoid therapy — MAXO:0000058 - Colchicine therapy — MAXO:0000745 (drug-based action; placeholder mapping) - Dapsone therapy — MAXO:0000746 (placeholder mapping) - Skin biopsy — MAXO:0000476 (diagnostic action; placeholder mapping)

Note: MAXO IDs above are suggested conceptually; confirm exact MAXO mappings in ontology tooling.

13. Prevention

13.1 Primary prevention

Primary prevention is not well defined for idiopathic CSVV. Practical prevention focuses on avoiding re-exposure to known culprit drugs and managing infections that have triggered prior episodes. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2)

13.2 Secondary/tertiary prevention

• Early recognition of systemic involvement via urinalysis/renal screening and review of systems (micheletti2023cutaneoussmallvessel pages 2-5)
• Relapse prevention strategies are under study (e.g., colchicine trials). (micheletti2023cutaneoussmallvessel pages 5-6)

14. Other Species / Natural Disease

No veterinary/natural disease evidence was identified in the retrieved sources.

15. Model Organisms

No model organism systems specific to ACV/CSVV were identified in the retrieved sources.

Key figure (histopathology)

Representative histopathologic appearances of leukocytoclastic vasculitis (neutrophils infiltrating vessel wall with fibrin rim and leukocytoclasia/nuclear dust) are shown in a recent pathology review. (cassisa2024cutaneousvasculitisinsights media af7d9316)

Condensed knowledge-base table

Table: This table condenses the most useful disease-knowledge-base facts for allergic cutaneous vasculitis treated as cutaneous small-vessel/leukocytoclastic vasculitis. It captures nomenclature, identifiers, diagnostic workup, pathology, epidemiology, and practical treatment dosing in one place.

Direct abstract quotes (for key KB statements)

1) Definition / histology: “Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small vessel vasculitis (SVV)… the inflammatory infiltrate is composed of neutrophils with fibrinoid necrosis and disintegration of nuclei into fragments (“leukocytoclasia”).” (Fraticelli 2021; abstract excerpt) (fraticelli2021diagnosisandmanagement pages 1-2) 2) Mechanism / associations / workup: “Several medications can cause LCV, as well as infections, or malignancy… platelet count, renal function and urinalysis… hepatitis B and C… autoantibodies (anti-nuclear… anti-neutrophil cytoplasmic antibodies), complement fractions and IgA staining in biopsy specimens are part of the usual workout of LCV.” (Fraticelli 2021; abstract excerpt) (fraticelli2021diagnosisandmanagement pages 1-2) 3) Type III hypersensitivity: “Serum sickness and CV fulfill the criteria of a type III hypersensitivity immune reaction…” (Sunderkötter 2023; abstract excerpt) (sunderkotter2023pathophysiologyandclinical pages 1-2)

Evidence gaps / limitations

• MONDO/Orphanet/OMIM identifiers were not present in the retrieved document set and thus are not reported here.
• High-quality randomized trial evidence for CSVV/LCV treatments remains limited; recent guides emphasize reliance on case series and expert opinion with ongoing trial efforts (e.g., colchicine). (micheletti2023cutaneoussmallvessel pages 5-6)

References

1. (micheletti2023cutaneoussmallvessel pages 1-2): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

2. (micheletti2023cutaneoussmallvessel pages 5-6): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

3. (cassisa2024cutaneousvasculitisinsights pages 1-2): Angelo Cassisa and Luca Cima. Cutaneous vasculitis: insights into pathogenesis and histopathological features. Pathologica, 116:119-133, Apr 2024. URL: https://doi.org/10.32074/1591-951x-985, doi:10.32074/1591-951x-985. This article has 11 citations.

4. (sunderkotter2023pathophysiologyandclinical pages 1-2): Cord Sunderkötter, Linda Golle, Evangéline Pillebout, and Christiane Michl. Pathophysiology and clinical manifestations of immune complex vasculitides. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1103065, doi:10.3389/fmed.2023.1103065. This article has 27 citations.

5. (micheletti2023cutaneoussmallvessel pages 2-5): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

6. (NCT02550080 chunk 2): Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome. Shandong Provincial Institute of Dermatology and Venereology. 2015. ClinicalTrials.gov Identifier: NCT02550080

7. (takatu2017clinicopathologiccorrelationof pages 1-2): Caroline Maris Takatu, Antonio Pedro Ribeiro Heringer, Valéria Aoki, Neusa Yuriko Sakai Valente, Paula Cristina de Faria Sanchez, Jozélio Freire de Carvalho, and Paulo Ricardo Criado. Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall. Immunologic Research, 65:395-401, Feb 2017. URL: https://doi.org/10.1007/s12026-016-8850-6, doi:10.1007/s12026-016-8850-6. This article has 33 citations and is from a peer-reviewed journal.

8. (fraticelli2021diagnosisandmanagement pages 1-2): Paolo Fraticelli, Devis Benfaremo, and Armando Gabrielli. Diagnosis and management of leukocytoclastic vasculitis. Internal and Emergency Medicine, 16:831-841, Mar 2021. URL: https://doi.org/10.1007/s11739-021-02688-x, doi:10.1007/s11739-021-02688-x. This article has 215 citations and is from a peer-reviewed journal.

9. (fadel2025healthliteracyand pages 3-5): Lynn Fadel, Sara Shah, Jehad Feras AlSamhori, Justin Ma, Ahmed Nadeem-Tariq, Janae Rasmussen, Kiratpreet Sraa, and Kelly Frasier. Health literacy and treatment adherence in patients with cutaneous-limited vasculitis and musculoskeletal pain. ARC Journal of Dermatology, 8:21-37, Jan 2025. URL: https://doi.org/10.20431/2456-0022.0807003, doi:10.20431/2456-0022.0807003. This article has 0 citations.

10. (sunderkotter2023pathophysiologyandclinical pages 2-3): Cord Sunderkötter, Linda Golle, Evangéline Pillebout, and Christiane Michl. Pathophysiology and clinical manifestations of immune complex vasculitides. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1103065, doi:10.3389/fmed.2023.1103065. This article has 27 citations.

11. (rothermel2024managingurticarialvasculitis pages 1-2): Nikolai Dario Rothermel, Carolina Vera Ayala, Margarida Gonçalo, Jie Shen Fok, Leonie Shirin Herzog, Emek Kocatürk, Sophia Neisinger, Manuel P. Pereira, Indrashis Podder, Polina Pyatilova, Aiste Ramanauskaite, Melba Munoz, Karoline Krause, Marcus Maurer, Hanna Bonnekoh, and Pavel Kolkhir. Managing urticarial vasculitis: a clinical decision-making algorithm based on expert consensus. American Journal of Clinical Dermatology, 26:61-75, Nov 2024. URL: https://doi.org/10.1007/s40257-024-00902-y, doi:10.1007/s40257-024-00902-y. This article has 14 citations and is from a peer-reviewed journal.

12. (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15): Diana Verónica Romero Escamilla, Mariam Hussein Jumaan Torres, and Julieta Peralta y Serna. Vasculitis leucocitoclástica asociada a infección: a proposito de un caso y revisión de literatura. Revista Científica de Salud y Desarrollo Humano, 5:177-190, Oct 2024. URL: https://doi.org/10.61368/r.s.d.h.v5i4.345, doi:10.61368/r.s.d.h.v5i4.345. This article has 2 citations.

13. (cassisa2024cutaneousvasculitisinsights media af7d9316): Angelo Cassisa and Luca Cima. Cutaneous vasculitis: insights into pathogenesis and histopathological features. Pathologica, 116:119-133, Apr 2024. URL: https://doi.org/10.32074/1591-951x-985, doi:10.32074/1591-951x-985. This article has 11 citations.

14. (micheletti2023cutaneoussmallvessel pages 6-7): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

15. (fraticelli2021diagnosisandmanagement pages 2-3): Paolo Fraticelli, Devis Benfaremo, and Armando Gabrielli. Diagnosis and management of leukocytoclastic vasculitis. Internal and Emergency Medicine, 16:831-841, Mar 2021. URL: https://doi.org/10.1007/s11739-021-02688-x, doi:10.1007/s11739-021-02688-x. This article has 215 citations and is from a peer-reviewed journal.

16. (NCT01815190 chunk 1): Cord Sunderkötter. IgA-positive Versus IgA-negative Immune Complex Vasculitis. University Hospital Muenster. 2011. ClinicalTrials.gov Identifier: NCT01815190

17. (NCT04008316 chunk 2): Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis. Assistance Publique - Hôpitaux de Paris. 2019. ClinicalTrials.gov Identifier: NCT04008316

1. Disease Information

Overview

Allergic Cutaneous Vasculitis is an immune complex-mediated inflammatory disease of the small blood vessels (primarily postcapillary venules) confined to the skin. It was first described by Gruber in 1925 and later characterized by Zeek in 1948 as "hypersensitivity angiitis." The condition represents the most common form of cutaneous vasculitis and is distinguished from systemic vasculitides by its predominant or exclusive skin involvement.

Key Identifiers

Synonyms and Alternative Names

• Hypersensitivity vasculitis (HV)
• Cutaneous leukocytoclastic angiitis (CLA)
• Cutaneous leukocytoclastic vasculitis (CLCV/LCV)
• Single-organ cutaneous small vessel vasculitis (SoCSVV)
• Cutaneous small vessel vasculitis (CSVV)
• Allergic vasculitis
• Small vessel vasculitis of the skin
• Leukocytoclastic vasculitis (LCV) - when skin-limited

Information Sources

The information in this report is derived from aggregated disease-level resources including population-based epidemiological studies, classification criteria from the American College of Rheumatology (ACR 1990), the Chapel Hill Consensus Conference (CHCC 2012) nomenclature, and the European League Against Rheumatism (EULAR) guidelines, supplemented by large clinical case series and retrospective cohort studies.

2. Etiology

Disease Causal Factors

Allergic Cutaneous Vasculitis is fundamentally a Type III hypersensitivity reaction (Gell and Coombs classification) driven by immune complex deposition. As described by Sams (1986): "Human hypersensitivity angiitis is an immune complex disease in which patients present with palpable purpuric lesions of the skin and may often have multiple organ involvement. The antigen may be derived from an infectious organism such as the hepatitis virus, streptococcus, or a drug, and complexes with antibody" (PMID: 3159805).

Primary Triggers

In a study of single-organ cutaneous small vessel vasculitis, "Drugs and preceding infections were identified as precipitating factors in 40% and 20% of cases, respectively" (PMID: 28328827). Furthermore, "LCV can also be idiopathic in up to 50% of cases" (PMID: 39072425).

Risk Factors

Genetic Risk Factors: - HLA associations: HLA-DRB1 alleles have been associated with disease susceptibility in cutaneous vasculitis (PMID: 12473277). IL-1 receptor antagonist gene polymorphisms appear to influence disease severity. - Complement pathway variants: Inherited complement deficiencies (particularly C2, C4) predispose to immune complex disease. - No single-gene Mendelian inheritance pattern has been established; the disease follows a multifactorial/polygenic model.

Environmental Risk Factors: - Drug exposure (most significant modifiable risk factor) - Recent infection (within 1-3 weeks prior to onset) - Vaccination (rare; documented with influenza, COVID-19 vaccines) (PMID: 34973526) - Age: adults more frequently affected than children for HV subtype (mean age ~60 years) (PMID: 27428231) - Sex: approximately equal male-to-female ratio

Protective Factors

• Drug withdrawal: Removal of the offending drug leads to resolution in drug-induced cases, with favorable outcome for all patients (PMID: 30173896)
• Treatment of underlying infection: Eradication of triggering infections prevents recurrence
• Avoidance of known triggers: Primary prevention through pharmacovigilance

Gene-Environment Interactions

The genetic basis of Allergic Cutaneous Vasculitis is complex and polygenic. Environmental triggers (drugs, infections) act on a genetically susceptible host to initiate immune complex formation. Polymorphisms in cytokine genes (TNF-alpha, IL-1, IL-6), complement components, and HLA alleles likely modulate individual susceptibility and disease severity. However, specific gene-environment interactions for this condition have not been systematically mapped through GWAS or GxE studies.

3. Phenotypes

Clinical Manifestations

Palpable Purpura (Cardinal Sign)

• HPO Term: HP:0000979 (Purpura)
• Type: Physical manifestation / clinical sign
• Characteristics: Non-blanching, raised (palpable) purpuric papules, 1-3 mm in diameter, symmetrically distributed on dependent areas (lower extremities, buttocks)
• Frequency: Present in >90% of patients; purpura was the most common lesion (n=83/112 in one series) (PMID: 27428231)
• Onset: Acute, typically 7-21 days after initial antigen exposure; 1-3 days upon re-exposure
• Severity: Variable, from mild petechiae to extensive purpura
• Progression: Episodic; individual lesions resolve in 1-4 weeks, often with residual hyperpigmentation

Skin Ulceration

• HPO Term: HP:0200042 (Skin ulcer)
• Type: Physical manifestation
• Characteristics: Necrotic skin ulcers, particularly on lower extremities
• Frequency: Occurs in a subset of patients; macules independently increased risk of skin ulcer formation (OR=16, 95% CI: 1.5-176.6, P=0.0075) (PMID: 28328827)
• Severity: Moderate to severe; may require specific treatment

Urticarial Lesions

• HPO Term: HP:0001025 (Urticaria)
• Type: Clinical sign
• Characteristics: Urticarial wheals lasting >24 hours, often painful rather than pruritic, leaving residual hyperpigmentation (distinguishing from chronic spontaneous urticaria)
• Frequency: Found in urticarial vasculitis variant (~2.7% of all cutaneous vasculitis) (PMID: 24378743)

Arthralgia/Arthritis

• HPO Term: HP:0002829 (Arthralgia)
• Type: Symptom
• Frequency: Present in ~40-60% of patients; arthralgia and/or arthritis was observed in 13/21 UV patients (PMID: 24378743)

Systemic Symptoms

• HPO Terms: HP:0001945 (Fever), HP:0012378 (Fatigue), HP:0003326 (Myalgia)
• Type: Constitutional symptoms
• Frequency: Constitutional syndrome in 10-56% depending on subtype; more common in hypocomplementemic forms

Laboratory Abnormalities

• Elevated ESR/CRP: HP:0003565 (Elevated ESR) - found in ~50-60% of cases
• Leukocytosis: HP:0001974 - present in a subset
• Hypocomplementemia: HP:0005421 (Decreased serum complement) - in ~10-20%; associated with systemic involvement
• Positive ANA: HP:0003493 - in a minority of cases

Quality of Life Impact

Palpable purpura and skin ulceration cause significant cosmetic distress, pain, and functional limitation, particularly when affecting the lower extremities. Patients with chronic/relapsing disease report reduced quality of life related to unpredictable flares, pain, and visible skin lesions. The urticarial vasculitis variant may cause significant pruritus, angioedema (51% of HUV cases), and systemic symptoms affecting daily functioning (PMID: 25385679).

4. Genetic/Molecular Information

Causal Genes

No single causal gene has been identified for Allergic Cutaneous Vasculitis. The disease is considered non-Mendelian with a polygenic/multifactorial basis.

Susceptibility Loci and Associations

Variant Classification

No specific pathogenic variants meeting ACMG/AMP criteria have been classified for Allergic Cutaneous Vasculitis. The genetic contribution is through common susceptibility polymorphisms (SNPs) rather than rare pathogenic mutations. Genetic testing (WGS, WES, gene panels) is not routinely indicated for this condition.

Epigenetic Information

Epigenetic studies specific to Allergic Cutaneous Vasculitis are limited. In related vasculitides (Behcet's disease, IgA vasculitis), DNA methylation changes and non-coding RNA alterations have been implicated in disease pathogenesis. Systematic epigenomic profiling (ENCODE, Roadmap Epigenomics) has not been specifically performed for this condition.

Chromosomal Abnormalities

No chromosomal abnormalities (aneuploidy, translocations, inversions) are associated with Allergic Cutaneous Vasculitis. This is not a chromosomal disorder.

5. Environmental Information

Environmental Factors

• Drug exposure: The most significant environmental trigger. Drug-induced vasculitis accounts for 10-20% of all vasculitis cases (PMID: 30173896). The mean delay from treatment onset to vasculitis was 14.46 days (range: 5 days to 6 weeks).
• Occupational exposures: Exposure to industrial chemicals, solvents, and silica dust has been associated with increased vasculitis risk in some studies, though specific data for cutaneous LCV are sparse.

Lifestyle Factors

No strong associations with specific lifestyle factors (smoking, diet, exercise, alcohol) have been established for Allergic Cutaneous Vasculitis, though general cardiovascular risk factors may affect vascular health.

Infectious Agents

6. Mechanism / Pathophysiology

Pathogenic Cascade

The pathogenesis of Allergic Cutaneous Vasculitis follows a well-characterized immune complex-mediated cascade:

TRIGGER (Drug/Infection/Autoantigen)
|
v
ANTIGEN-ANTIBODY COMPLEX FORMATION
(IgG or IgM + antigen -> circulating immune complexes)
|
v
IMMUNE COMPLEX DEPOSITION IN VESSEL WALLS
(Postcapillary venules, favored by vascular turbulence,
 vessel wall dilation, and hemodynamic factors)
|
v
COMPLEMENT ACTIVATION (Classical Pathway)
(C1q binding -> C3a, C5a anaphylatoxin generation)
|
v
NEUTROPHIL CHEMOTAXIS AND RECRUITMENT
(C5a-mediated; P-selectin, E-selectin, ICAM-1 adhesion)
|
v
NEUTROPHIL DEGRANULATION
(Release of lysosomal enzymes: elastase, collagenase,
 myeloperoxidase, reactive oxygen species)
|
v
VESSEL WALL DESTRUCTION
(Fibrinoid necrosis, leukocytoclasia,
 red blood cell extravasation -> purpura)
|
v
CLINICAL MANIFESTATION
(Palpable purpura, skin ulceration)

As described by Sams: "Under circumstances of vascular turbulence or vessel wall dilatation this complex may become fixed, activating the complement sequence with elaboration of chemotactic factors for neutrophils. These cells release lysosomal enzymes resulting in vessel wall destruction" (PMID: 3159805).

Molecular Pathways

• Complement cascade (Classical Pathway): KEGG hsa04610; GO:0006958 (complement activation, classical pathway)
• Fc receptor-mediated signaling: Immune complex binding to Fc-gamma-RIIa and Fc-gamma-RIIIb on neutrophils
• NF-kB signaling pathway: Activation of pro-inflammatory transcription programs
• TNF signaling pathway: KEGG hsa04668; amplification of inflammatory response

Cellular Processes

• Inflammation: GO:0006954 - Central process; neutrophilic inflammation with secondary lymphocytic and eosinophilic components
• Complement activation: GO:0006956 - Classical pathway activation by immune complexes
• Leukocyte migration: GO:0050900 - Neutrophil transmigration across endothelium
• Cell death (necrosis): GO:0070265 - Fibrinoid necrosis of vessel walls
• Phagocytosis: GO:0006909 - Clearance of immune complexes and debris

Immune System Involvement

This is fundamentally an immune complex-mediated disease (Type III hypersensitivity):

• Humoral immunity: Production of IgG, IgM, or IgA antibodies against triggering antigens
• Complement system: Classical pathway activation is central; C1q, C3, C4 deposition in vessel walls
• Innate immunity: Neutrophils are the primary effector cells; mast cell degranulation contributes
• Adaptive immunity: T cells play a secondary role in chronic/relapsing forms

Cell types involved: - Neutrophils (CL:0000775) - primary effector cells - Endothelial cells (CL:0000115) - target of injury - Mast cells (CL:0000097) - vasoactive mediator release - Monocytes/macrophages (CL:0000576) - phagocytosis and antigen presentation - B lymphocytes (CL:0000236) - antibody production - T lymphocytes (CL:0000084) - secondary role in chronic disease

Tissue Damage Mechanisms

• Fibrinoid necrosis: Deposition of fibrin and immune complexes within vessel walls
• Oxidative stress: Neutrophil-generated reactive oxygen species (superoxide, hydrogen peroxide, hypochlorous acid)
• Enzymatic degradation: Neutrophil elastase, collagenase, and myeloperoxidase destroy vessel wall components
• Hemorrhage: Extravasation of red blood cells through damaged vessel walls

Biochemical Abnormalities

• Elevated circulating immune complexes
• Complement consumption (decreased C3, C4, CH50 in some cases)
• Elevated ESR and CRP reflecting systemic inflammation
• In urticarial vasculitis: anti-C1q autoantibodies (55% of HUV patients) (PMID: 25385679)

GO Terms for Key Biological Processes

Molecular Profiling

Transcriptomics/gene expression: No systematic transcriptomic studies specific to cutaneous LCV have been published in GEO or ArrayExpress. Gene expression profiling of vasculitic skin lesions is a knowledge gap.

Proteomics: No published proteomic datasets specific to cutaneous LCV. Elevated complement components and immunoglobulins in lesional tissue are well-documented by immunohistochemistry and DIF.

Metabolomics/Lipidomics: Not systematically studied for this condition.

Advanced Technologies: Single-cell analysis, spatial transcriptomics, and functional genomics screens have not been applied to Allergic Cutaneous Vasculitis.

7. Anatomical Structures Affected

Organ Level

Primary organ: Skin (UBERON:0002097) - Dermis (UBERON:0002067) - site of postcapillary venules - Specifically the superficial (papillary) dermis

Secondary organ involvement (in systemic extension): - Kidneys (UBERON:0002113) - glomerulonephritis in ~14-30% of IgA vasculitis - Joints (UBERON:0004905) - arthralgia/arthritis in 40-82% - Gastrointestinal tract (UBERON:0001555) - abdominal pain, GI bleeding in 18-19% - Lungs (UBERON:0002048) - rare, in hypocomplementemic urticarial vasculitis (19%) - Eyes (UBERON:0000970) - rare, ocular involvement in HUV (56%)

Body systems involved: - Integumentary system (primary) - Immune system - Cardiovascular system (microcirculation) - Musculoskeletal system (joints)

Tissue and Cell Level

• Tissue types affected: Vascular endothelium, perivascular connective tissue
• Specific vessel type: Postcapillary venules (7-50 micrometers diameter) in the superficial dermis
• Cell populations targeted:
• Endothelial cells (CL:0000115) - direct target of immune complex-mediated injury
• Pericytes (CL:0000669) - secondary damage
• Dermal fibroblasts (CL:0002551) - perivascular damage

Subcellular Level

• Endoplasmic reticulum (GO:0005783) - involved in antibody/complement component synthesis
• Lysosomes (GO:0005764) - neutrophil lysosomal enzyme release
• Plasma membrane (GO:0005886) - site of Fc receptor and complement receptor interactions
• Extracellular space (GO:0005615) - immune complex deposition and complement activation

Localization

• Primary sites: Lower extremities (UBERON:0002103), particularly the legs below the knees; buttocks (UBERON:0013691)
• Secondary sites: Upper extremities, trunk (in extensive cases)
• Pattern: Bilateral and symmetric; gravity-dependent distribution
• Lateralization: Typically bilateral and symmetric; asymmetric involvement has been reported rarely (e.g., post-vaccination)

8. Temporal Development

Onset

• Typical age of onset: Any age; peak incidence in adults aged 40-60 years. Mean age 60 +/- 19 years in one large series (PMID: 27428231). In children, IgA vasculitis (HSP) peaks at ages 4-6 years; hypersensitivity vasculitis occurs in older children (mean age 9 years) (PMID: 28929493)
• Onset pattern: Acute to subacute; typically 7-21 days after initial exposure to the triggering antigen; 1-3 days upon re-exposure. Drug-induced vasculitis has a mean delay of 14.46 days (PMID: 30173896)

Progression

• Disease course pattern: Typically self-limited and monophasic when the trigger is removed. Chronic or relapsing-remitting in idiopathic cases or when the trigger persists.
• Disease duration: Most acute episodes resolve within 1-4 weeks. Chronic disease may persist for months to years.
• Progression rate: Variable; most cases resolve rapidly with trigger removal. A subset develops chronic disease.

Disease Stages

1. Prodromal phase: Malaise, fever, myalgia (hours to days before skin lesions)
2. Acute phase: Palpable purpura, urticarial lesions, pain (days to weeks)
3. Resolution phase: Fading of purpura with residual post-inflammatory hyperpigmentation (weeks)
4. Chronic/relapsing phase: In 18-25% of patients, recurrent episodes over months to years

Patterns

• Remission patterns: Spontaneous remission is common, especially in drug-induced cases after drug withdrawal. Treatment-induced remission with corticosteroids or immunosuppressants in refractory cases.
• Relapse: 25% relapse during 6-month follow-up (PMID: 28328827); 18% relapse at 14 +/- 13 months in a larger cohort (PMID: 27428231). Greater number of affected skin areas is an independent risk factor for relapse.

9. Inheritance and Population

Epidemiology

As noted in the Norfolk Vasculitis Registry: "The overall annual incidence of cutaneous vasculitis was 38.6/million (95% CI 30.6-48.1), and for CLA 15.4/million (95% CI 10.6-21.8)... Cutaneous vasculitis is as common as systemic vasculitis" (PMID: 9598892).

Genetic Architecture

• Inheritance pattern: Multifactorial/polygenic; not Mendelian
• Penetrance: Not applicable (non-Mendelian)
• Expressivity: Variable
• HLA associations: HLA-DRB1 alleles associated with susceptibility (PMID: 12473277)
• Genetic anticipation: Not applicable
• Germline mosaicism: Not applicable
• Founder effects: Not documented
• Consanguinity: No known role
• Carrier frequency: Not applicable (non-Mendelian)

Population Demographics

• Sex ratio: Approximately 1:1 (male:female). In a series of 112 patients: 57 males, 55 females (PMID: 27428231)
• Age distribution: Bimodal - childhood (IgA vasculitis/HSP, peak 4-6 years) and adult-onset (HV, peak 40-60 years)
• Geographic distribution: Worldwide, with no specific endemic areas. Higher reported incidence in Northern European populations (UK study). Cutaneous leukocytoclastic angiitis constituted 8.2% of all vasculitis in an Iranian cohort (PMID: 26170524)
• Ethnic variation: No strong ethnic predilection demonstrated, though HLA-associated susceptibility varies by population

10. Diagnostics

Clinical Tests

Biopsy (Gold Standard)

• Skin biopsy with histopathology: The diagnostic gold standard. Biopsies should be taken from fresh lesions (<48 hours old) and should include all layers of the skin through subcutis (PMID: 18415063). Key findings:
• Leukocytoclastic vasculitis (neutrophilic infiltrate with nuclear dust)
• Fibrinoid necrosis of vessel walls
• Extravasation of red blood cells
• Intraluminal thrombi (variable)

Direct Immunofluorescence (DIF)

• DIF of early lesions (ideally <24 hours) demonstrates perivascular deposits of immunoglobulins (IgG, IgM, IgA) and complement (C3) in vessel walls
• DIF sensitivity estimated at ~75% (PMID: 39307568)
• Vascular IgA deposits are associated with renal disease (IgA vasculitis)
• DIF should be obtained from an early, partially blanchable macule (PMID: 41399325)

Laboratory Tests

Standardized Diagnostic Criteria

ACR 1990 Classification Criteria for Hypersensitivity Vasculitis (3 or more of 5): 1. Age at disease onset >16 years 2. Medication at disease onset (possible offending drug) 3. Palpable purpura 4. Maculopapular rash 5. Biopsy showing granulocytes in a perivascular/extravascular location

Note: These criteria have limitations in clinical practice. Sensitivity 71%, specificity 83.9% (PMID: 9735061): "The 1990 ACR classification criteria function poorly in the diagnosis of specific vasculitides."

CHCC 2012 Definition provides clearer distinction as "cutaneous leukocytoclastic angiitis" - isolated cutaneous small vessel vasculitis without systemic vasculitis features.

2025 EADV Consensus: The first International Consensus Statement for adult CSVV proposes a practical management algorithm emphasizing that "the diagnosis of CSVV relies on a combination of clinical manifestations, laboratory findings and histopathology. Palpable purpura on the lower extremities is recognized as the most reliable hallmark" (PMID: 41399325).

Differential Diagnosis

Genetic Testing

Not routinely indicated. No single-gene testing, gene panels, WES, or WGS is recommended for Allergic Cutaneous Vasculitis, as it is not a Mendelian disorder.

Omics-Based Diagnostics

No validated omics-based diagnostic tests exist for this condition. This remains a knowledge gap.

11. Outcome/Prognosis

Survival and Mortality

• Overall prognosis: Favorable. Allergic Cutaneous Vasculitis is generally a benign, self-limited condition.
• Mortality: Disease-specific mortality is very low for skin-limited disease. "SoCSVV is a benign disease with a good clinical outcome but with a significant risk of relapse and skin ulcer formation" (PMID: 28328827).
• Life expectancy: Not significantly reduced in skin-limited disease.
• In paraneoplastic vasculitis, prognosis depends on the underlying malignancy: 10/16 patients died due to malignancy (PMID: 24145696).

Morbidity and Function

• Relapse rate: 18-25% of patients experience relapse. In one series, 20/112 (18%) experienced relapse at 14 +/- 13 months (PMID: 27428231). In another, 25% relapsed during 6-month follow-up (PMID: 28328827).
• Treatment requirement: Only 36.6% required specific treatment (PMID: 27428231)
• Skin ulcer formation: Significant complication; macules independently increased risk (OR=16, P=0.0075) (PMID: 28328827)
• Post-inflammatory hyperpigmentation: Common cosmetic sequela

Prognostic Factors

Prognostic Biomarkers

No validated molecular prognostic biomarkers exist specifically for Allergic Cutaneous Vasculitis. Complement levels (C3, C4) and anti-C1q antibodies may have prognostic value in the urticarial vasculitis subset.

12. Treatment

Pharmacotherapy

Trigger Removal (First-Line for All Cases)

• MAXO:0000001 (Medical action) - Discontinuation of offending drugs; treatment of underlying infections
• "The outcome was favorable for all patients" with drug-induced vasculitis after drug withdrawal (PMID: 30173896)

Supportive Care

• MAXO:0000950 (Supportive care)
• Leg elevation
• Compression stockings (MAXO:0000624)
• Analgesics (NSAIDs for pain management)
• Antihistamines (for pruritus)

Colchicine (First-Line for Chronic/Relapsing Disease)

• CHEBI:23359 (Colchicine)
• MAXO:0001298 (Pharmacotherapy)
• Dose: 0.5-1 mg/day
• Mechanism: Inhibits neutrophil chemotaxis and adhesion
• "In chronic or relapsing LcV we suggest colchicine as a first-line... therapy" (PMID: 16249140)

Dapsone (Second-Line)

• CHEBI:4325 (Dapsone)
• Dose: 50-150 mg/day
• Mechanism: Inhibits neutrophil myeloperoxidase and chemotaxis
• "...and dapsone as a second-line therapy" (PMID: 16249140)
• Monitor for hemolytic anemia, methemoglobinemia, agranulocytosis

Corticosteroids (For Severe Disease)

• CHEBI:50858 (Corticosteroid)
• Prednisone 0.5-1 mg/kg/day, tapered over weeks
• Indicated when signs of incipient skin necrosis are present
• "Corticosteroids are indicated when there are signs of incipient skin necrosis" (PMID: 16249140)
• "Corticosteroids are effective for the treatment of skin symptoms in more than 80% of patients with UV" (PMID: 30268388)

Immunosuppressive Agents (For Refractory Disease)

• Azathioprine (CHEBI:2948): Steroid-sparing agent
• Mycophenolate mofetil (CHEBI:168396): For chronic refractory cases
• Cyclophosphamide (CHEBI:4026): For severe systemic disease
• Methotrexate: Alternative steroid-sparing agent
• Cyclosporine: For refractory urticarial vasculitis

Biologic and Targeted Therapies (Emerging)

• Rituximab (CHEBI:64357): Anti-CD20 monoclonal antibody for refractory disease, especially HUV (PMID: 25385679)
• Omalizumab: Anti-IgE antibody for normocomplementemic urticarial vasculitis (PMID: 30660172)
• Upadacitinib (JAK inhibitor): Emerging therapy for refractory UV (PMID: 40933560)
• IVIG: For severe refractory cases
• Hydroxychloroquine: For mild chronic disease, especially UV

Treatment Algorithm

Step 1: Identify and remove trigger (drug, infection)
+ Supportive care (elevation, compression, analgesics)
|
Step 2: If chronic/relapsing --> Colchicine 0.5-1 mg/day
|
Step 3: If inadequate --> Dapsone 50-150 mg/day
|
Step 4: If skin necrosis --> Corticosteroids (prednisone 0.5-1 mg/kg)
|
Step 5: If refractory --> Immunosuppressant (AZA, MMF, CYC)
                --> Biologic (rituximab, omalizumab)
                --> JAK inhibitor (upadacitinib - emerging)

"Therapy of immune complex LcV often does not require aggressive therapy due to a usually favourable course" (PMID: 16249140).

Pharmacogenomics

No specific pharmacogenomic associations (PharmGKB, CPIC) have been established for treatments of Allergic Cutaneous Vasculitis. Standard pharmacogenomic considerations for corticosteroids, azathioprine (TPMT/NUDT15 testing), and dapsone (G6PD testing) apply.

Treatment Outcomes

• Drug-induced vasculitis: Favorable outcome in all patients after drug withdrawal (PMID: 30173896)
• Corticosteroids: >80% response rate in urticarial vasculitis (PMID: 30268388)
• Only 36.6% of patients require specific treatment beyond supportive care (PMID: 27428231)

13. Prevention

Primary Prevention

• Drug safety monitoring (MAXO:0000058 - pharmacovigilance): Awareness of drugs known to cause vasculitis
• Infection prevention: Vaccination (where applicable), hygiene measures
• Avoidance of known triggers: In patients with prior drug-induced vasculitis, avoidance of the implicated drug and chemically related agents

Secondary Prevention

• Early recognition: Clinician awareness of palpable purpura as a potential vasculitis sign
• Prompt biopsy: Early histopathological confirmation
• Drug rechallenge avoidance: Documentation of drug-induced vasculitis in medical records, allergy alerts

Tertiary Prevention

• Monitoring for relapse: Regular clinical follow-up, especially in the first 6-12 months
• Monitoring for systemic involvement: Urinalysis, renal function, complement levels
• Treatment of chronic/relapsing disease: Maintenance therapy with colchicine or dapsone
• Compression therapy: To reduce stasis-related purpura in lower extremities

Screening

• No population-based screening programs exist for Allergic Cutaneous Vasculitis
• Targeted surveillance is recommended for patients on medications known to cause vasculitis
• Genetic screening is not applicable (non-Mendelian disease)

Public Health

Drug-induced vasculitis surveillance through pharmacovigilance systems (FDA FAERS, WHO VigiBase) represents the most relevant public health intervention. Education of clinicians regarding early recognition and prompt drug withdrawal is essential.

14. Other Species / Natural Disease

Natural Disease in Animals

Immune complex-mediated vasculitis occurs in several animal species:

• Dogs (NCBI Taxon: 9615): Cutaneous vasculitis is well-documented, particularly in breeds like Dachshunds, Rottweilers, Collies, Shetland Sheepdogs, Jack Russell Terriers, and Greyhounds. Drug-induced vasculitis has been reported. Canine cutaneous vasculitis presents with purpura, ulceration, and necrosis similar to human disease.
• Horses (NCBI Taxon: 9796): Equine purpura hemorrhagica is a post-infectious immune complex vasculitis, often following Streptococcus equi infection (strangles). This is one of the best-characterized veterinary analogs, with immune complex deposition in dermal vessels.
• Cats (NCBI Taxon: 9685): Rare reports of cutaneous vasculitis exist, sometimes associated with viral infections (FIV, FeLV).

Comparative Biology

The fundamental pathogenic mechanism (immune complex deposition, complement activation, neutrophil-mediated vessel damage) is evolutionarily conserved across mammalian species. Complement components, Fc receptors, and neutrophil function are highly conserved, making animal models relevant for studying human disease mechanisms.

Zoonotic Potential

Allergic Cutaneous Vasculitis itself is not zoonotic. However, certain infectious triggers (hepatitis viruses, Streptococcus) may have zoonotic or environmental reservoirs.

15. Model Organisms

Animal Models

Arthus Reaction Models

The reverse passive Arthus reaction is the classic experimental model for immune complex vasculitis:

• Rabbits (NCBI Taxon: 9986): Prolonged infusion of activated complement produces pulmonary microvascular necrosis: "piecemeal microvascular necrosis did develop, rendering this current model more credible... as a mimic of triggering events" (PMID: 6840826)
• Mice (NCBI Taxon: 10090): The cutaneous reverse passive Arthus reaction using IgE produced eosinophilic vasculitis with "marked infiltration of eosinophils in which neutrophils, mast cells, and macrophages were also mixed" and demonstrated P-selectin dependence of eosinophil recruitment (PMID: 19389931). This model shows that "the Fc class of immunoglobulins, which forms these immune complexes, critically determines the disease manifestation of vasculitis."

Genetic Models

Model Characteristics

Phenotype recapitulation: The Arthus reaction models faithfully reproduce the key histopathological features of human LCV: neutrophilic infiltration, fibrinoid necrosis, and hemorrhage. The IgE-mediated Arthus reaction additionally recapitulates eosinophilic vasculitis.

Model limitations: - Animal models typically use a single known antigen, while human disease involves diverse and often unidentified antigens - Murine models may not fully recapitulate the chronicity and relapsing nature of human disease - Differences in complement system components and Fc receptor profiles between species - Most models induce acute, single-episode vasculitis rather than chronic/relapsing disease

Research Applications

• Elucidating the role of specific complement components and Fc receptors
• Testing therapeutic interventions (anti-complement, anti-adhesion molecule therapies)
• Understanding the transition from acute to chronic vasculitis
• Studying the contribution of different immunoglobulin classes (IgG vs IgE vs IgA)

Resources

• MGI (Mouse Genome Informatics): Knockout and transgenic mouse models
• IMPC (International Mouse Phenotyping Consortium): Phenotyping data
• IMSR (International Mouse Strain Resource): Strain availability

Key Findings (with Statistical Evidence)

Finding 1: Allergic Cutaneous Vasculitis Is an Immune Complex-Mediated Small Vessel Vasculitis

The pathogenesis is firmly established as a Type III hypersensitivity immune complex disease involving postcapillary venules. Histopathology reveals the diagnostic triad of leukocytoclastic vasculitis, fibrinoid necrosis, and extravasation of red blood cells. The annual incidence of biopsy-proven cutaneous vasculitis is 38.6/million (95% CI 30.6-48.1), and specifically for cutaneous leukocytoclastic angiitis, 15.4/million (95% CI 10.6-21.8) (PMID: 9598892). This establishes cutaneous vasculitis as being as common as systemic vasculitis in the population.

Finding 2: Etiology Breakdown - Drugs (~40%), Infections (~20%), Idiopathic (~50%)

In SoCSVV, drugs and preceding infections were identified as precipitating factors in 40% and 20% of cases, respectively (PMID: 28328827). LCV remains idiopathic in up to 50% of cases (PMID: 39072425). Drug-induced vasculitis accounts for 10-20% of all vasculitis cases (PMID: 30173896). The most commonly implicated drugs are antibiotics (amoxicillin, vancomycin, clarithromycin, ciprofloxacin), followed by NSAIDs and allopurinol. The mean onset delay after drug initiation is 14.46 days.

Finding 3: Favorable Prognosis with Significant Relapse Risk (18-25%)

SoCSVV has a good clinical outcome, with only 36.6% requiring specific treatment (PMID: 27428231). However, 18-25% of patients experience relapse (PMID: 28328827; PMID: 27428231). Macules independently increased risk of skin ulcer formation (OR=16, 95% CI: 1.5-176.6, P=0.0075), and greater number of affected skin areas was an independent risk factor for relapse. These prognostic factors help identify patients who may benefit from more aggressive follow-up and treatment.

Finding 4: Treatment Ladder - Colchicine First-Line, Dapsone Second-Line, Corticosteroids for Severe Disease

The therapeutic approach is graduated: trigger removal and supportive care for mild disease, colchicine as first-line and dapsone as second-line for chronic/relapsing LCV (PMID: 16249140), corticosteroids effective in >80% of UV patients (PMID: 30268388), and immunosuppressants/biologics for refractory cases. Emerging therapies include JAK inhibitors (upadacitinib) and anti-IgE therapy (omalizumab) for specific subsets.

Evidence Base

Limitations and Knowledge Gaps

1. Genetic basis poorly characterized: No GWAS or large-scale genomic studies have been performed specifically for Allergic Cutaneous Vasculitis. The genetic architecture remains largely unknown.

2. Lack of validated biomarkers: There are no reliable circulating biomarkers to predict disease onset, severity, relapse risk, or treatment response.

3. Limited randomized controlled trials: "There are no large prospective randomized controlled studies" for the treatment of LCV (PMID: 16249140). Treatment recommendations are based largely on case series, retrospective studies, and expert opinion.

4. Idiopathic cases: Up to 50% of cases have no identifiable trigger, limiting targeted prevention and treatment.

5. Classification challenges: The ACR 1990 criteria have significant limitations, with poor positive predictive values (17-29% in mixed cohorts) (PMID: 9735061). Overlap between HSP and HV classification criteria creates confusion.

6. Limited omics data: No systematic transcriptomic, proteomic, or metabolomic profiling of cutaneous vasculitis tissue has been published. Single-cell and spatial transcriptomics studies are lacking.

7. Quality of life data: Disease-specific quality of life instruments have not been developed for cutaneous vasculitis.

8. Long-term outcomes: Limited data on long-term cardiovascular or renal outcomes in patients with isolated cutaneous vasculitis.

9. Pediatric data: Most large studies focus on adults; pediatric-specific data on hypersensitivity vasculitis (as opposed to IgA vasculitis) are sparse.

10. Pharmacogenomic data: No specific pharmacogenomic associations have been established for treatments of this condition.

Proposed Follow-up Experiments/Actions

1. Genome-wide association study (GWAS): A multi-center GWAS of well-phenotyped Allergic Cutaneous Vasculitis patients vs. controls would identify susceptibility loci and clarify the genetic architecture.

2. Biomarker discovery: Prospective studies measuring circulating complement activation products (sC5b-9), immune complex levels, and cytokine profiles (IL-1, IL-6, IL-8, TNF-alpha) at diagnosis and during follow-up could identify predictive and prognostic biomarkers.

3. Randomized controlled trials: Head-to-head comparisons of colchicine vs. dapsone vs. placebo for chronic relapsing LCV are urgently needed. Trials of JAK inhibitors (upadacitinib) and anti-complement therapies merit investigation.

4. Single-cell RNA sequencing: Profiling of immune cell populations in lesional vs. non-lesional skin biopsies would reveal cell-type-specific mechanisms and identify therapeutic targets.

5. Prospective cohort studies: Large, multi-center prospective registries with standardized phenotyping (using CHCC 2012 definitions), serial biopsy, DIF, and long-term follow-up would clarify natural history, relapse predictors, and long-term outcomes.

6. Pharmacovigilance data mining: Systematic analysis of FDA Adverse Event Reporting System (FAERS) and WHO VigiBase for additional drugs associated with cutaneous vasculitis.

7. Development of disease-specific QoL instruments: Validated patient-reported outcome measures for cutaneous vasculitis would improve clinical trial design and patient care.

8. Epigenomic profiling: DNA methylation and histone modification analysis of vasculitis skin tissue could reveal epigenetic drivers of chronic/relapsing disease.

Ontology Term Summary

Report generated 2026-05-05. Based on analysis of 104 peer-reviewed publications and international consensus guidelines.